Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18259130 | 0.86 | KMO (1.00) | KMOHTTTSHRUSP2ALDH1A1 | |
| SCHEMBL7276060 | 0.83 | TSHR (1.00) | HTTTSHRALDH1A1POLBMEN1 | |
| SCHEMBL8263744 | 0.83 | HTT (0.71) | KMOHTTTSHRUSP2ALDH1A1 | |
| SCHEMBL2956116 | 0.83 | HTT (0.63) | KMOHTTTSHRUSP2ALDH1A1 | |
| SCHEMBL5346335 | 0.82 | HTT (0.70) | KMOHTTTSHRUSP2ALDH1A1 | |
| SCHEMBL12203796 | 0.81 | USP2 (0.67) | KMOHTTTSHRUSP2THRB | |
| SCHEMBL13779978 | 0.80 | MEN1 (0.66) | KMOHTTTSHRUSP2POLB | |
| SCHEMBL3893315 | 0.80 | KMO (0.79) | KMOHTTTSHRUSP2THRB | |
| SCHEMBL2947181 | 0.80 | HTT (0.70) | KMOHTTTSHRUSP2ALDH1A1 | |
| SCHEMBL30808661 | 0.80 | KMT2A (0.68) | HTTTSHRUSP2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078358-B2 | Curable composition including epoxy resin and curable solid filler | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3661990-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M Innovative Properties Company (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200148878-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M INNOVATIVE PROPERTIES COMPANY | 2020-05-14 | — | — | US | disclosed |
| CN-110997748-A | Curable composition comprising an epoxy resin and a curable solid filler | 3M创新有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019027746-A1 | CURABLE COMPOSITION INCLUDING EPOXY RESIN AND CURABLE SOLID FILLER | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-02-07 | — | — | WO | disclosed |
| EP-2670765-B1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2017-10-18 | — | — | EP | disclosed |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-8846647-B2 | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2670765-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | Bristol-Myers Squibb Company (US) | 2013-12-11 | — | — | EP | disclosed |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-07 | — | — | US | disclosed |
| WO-2012106190-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, CDK17 | KMO 2868/4885HTT 4863/4885TSHR 4746/4885 |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | KMO 2732/4885HTT 4847/4885TSHR 4796/4885 |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | KMO 2732/4885HTT 4847/4885TSHR 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.